Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Neoplasm Metastasis 5Colorectal Neoplasms 5Pancreatic Neoplasms 4Sarcoma 3Insulin-Like Growth Factor I, Resistance To 3Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Adenocarcinoma 2Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Pleural Effusion, Malignant 1Neuroectodermal Tumors, Primitive 1Melanoma 1Lymphoma 1Lung Neoplasms 1Jaundice 1Gastrointestinal Neoplasms 1Endocrine Gland Neoplasms 1Carcinoid Tumor 1Askin Tumor 1

Interventions

pembrolizumab 166Nivolumab 111Ipilimumab 93Dacarbazine 44trametinib 36dabrafenib 34Vemurafenib 33binimetinib 23atezolizumab 23Temozolomide 21cemiplimab 18Paclitaxel 18encorafenib 17spartalizumab 16cobimetinib 15Carboplatin 14talimogene laherparepvec 13Cisplatin 13Cyclophosphamide 12lenvatinib 10Pemetrexed 10Gemcitabine 10Docetaxel 10durvalumab 9Drug Therapy 9Bevacizumab 9tremelimumab 8Injections 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Melanoma × ganitumab × Clear all
NCT01562899 2020-12-10

A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

Pfizer

Phase 1/2 Terminated
77 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡